RCT: Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder.
19 Apr, 2022 | 01:20h | UTCSafety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial – The Lancet Neurology (link to abstract – $ for full-text)